Analysts’ Top Healthcare Picks: Crispr Therapeutics AG (CRSP), Faeth Therapeutics (FTH)
Analysts at H.C. Wainwright and J.P. Morgan reiterated Buy ratings on Crispr Therapeutics (CRSP) with price targets of $80 and $73.09, respectively. Faeth Therapeutics (FTH) received a Buy rating and $55 price target from JonesTrading, with a consensus target of $57.60. Both stocks have significant upside potential according to analysts.
How this was made
The 30-second read
Why it matters
Analyst upgrades can trigger short-term buying pressure, especially for small‑cap biotech stocks where coverage is scarce.
Market read
Both stocks receive fresh, higher price targets, offering a short‑term trade idea for bullish investors in the healthcare sector.
What to watch
Potential regulatory or clinical trial setbacks could negate the upside.
Background
The article summarizes fresh analyst coverage for two biotech firms, providing new price targets and reaffirmed Buy ratings.
Ticker impact
Analyst Mitchell Kapoor reiterated a Buy rating and set a new $80 price target for Crispr Therapeutics AG, up from the prior level.
likely upward pressure as investors price in the $80 target.
Buy rating and a 57% upside target constitute fresh, material analyst coverage.
Analyst Boris Peaker maintained a Buy rating and raised the price target to $55 for Faeth Therapeutics.
likely upward pressure as the $55 target implies a 177% upside.
New rating and target provide fresh catalyst for the stock.
Market effects
Both upgrades highlight continued bullish sentiment in the healthcare/biotech sector.
U.S. biotech investors may reallocate capital toward CRSP and FTH.
Limited to investors tracking biotech equities; no broader macro effect.
Counterpoint
The price targets may be overly optimistic given the companies' early-stage pipelines.
Key entities
- companyCrispr Therapeutics AG
Gene‑editing biotech with a new $80 price target.
- companyFaeth Therapeutics
Biotech firm receiving a $55 price target.

